Joel M. Kremer

Suggest Changes
Learn More
JASVINDER A. SINGH, DANIEL E. FURST, ASEEM BHARAT, JEFFREY R. CURTIS, ARTHUR F. KAVANAUGH, JOEL M. KREMER, LARRY W. MORELAND, JAMES O’DELL, KEVIN L. WINTHROP, TIMOTHY BEUKELMAN, S. LOUIS BRIDGES JR.,(More)
OBJECTIVE To assess the efficacy and safety of tocilizumab plus methotrexate (MTX) versus MTX alone in preventing structural joint damage and improving physical function and disease activity in(More)
OBJECTIVE To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP-690,550) with placebo for the treatment of active rheumatoid arthritis (RA) in patients receiving a(More)
OBJECTIVE To determine the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom(More)